ARTICLE | Company News
FDA adds warnings to SGLT2 inhibitors' labels
December 5, 2015 2:09 AM UTC
FDA added warnings to the labels of sodium-glucose transporter 2 ( SGLT2) inhibitors about the risks of ketoacidosis and serious urinary tract infections. Marketed Type II diabetes drugs in the class include Jardiance empagliflozin from Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY); Invokana canaglifozin from Johnson & Johnson (NYSE:JNJ); and Farxiga dapagliflozin from AstraZeneca plc (LSE:AZN; NYSE:AZN). ...